293 related articles for article (PubMed ID: 18538175)
1. Potential mechanisms of resistance to microtubule inhibitors.
Kavallaris M; Annereau JP; Barret JM
Semin Oncol; 2008 Jun; 35(3 Suppl 3):S22-7. PubMed ID: 18538175
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics, metabolites, and preclinical safety of vinflunine.
Lobert S; Puozzo C
Semin Oncol; 2008 Jun; 35(3 Suppl 3):S28-33. PubMed ID: 18538176
[TBL] [Abstract][Full Text] [Related]
3. Exploring the mechanisms of action of the novel microtubule inhibitor vinflunine.
Jordan MA; Horwitz SB; Lobert S; Correia JJ
Semin Oncol; 2008 Jun; 35(3 Suppl 3):S6-S12. PubMed ID: 18538179
[TBL] [Abstract][Full Text] [Related]
4. Novel actions of the antitumor drugs vinflunine and vinorelbine on microtubules.
Ngan VK; Bellman K; Panda D; Hill BT; Jordan MA; Wilson L
Cancer Res; 2000 Sep; 60(18):5045-51. PubMed ID: 11016627
[TBL] [Abstract][Full Text] [Related]
5. Introduction. The novel microtubule inhibitor vinflunine.
Horwitz SB
Semin Oncol; 2008 Jun; 35(3 Suppl 3):S1-2. PubMed ID: 18538173
[No Abstract] [Full Text] [Related]
6. Vinflunine, a new vinca alkaloid: cytotoxicity, cellular accumulation and action on the interphasic and mitotic microtubule cytoskeleton of PtK2 cells.
Jean-Decoster C; Brichese L; Barret JM; Tollon Y; Kruczynski A; Hill BT; Wright M
Anticancer Drugs; 1999 Jul; 10(6):537-43. PubMed ID: 10885901
[TBL] [Abstract][Full Text] [Related]
7. Vinflunine, the latest Vinca alkaloid in clinical development. A review of its preclinical anticancer properties.
Kruczynski A; Hill BT
Crit Rev Oncol Hematol; 2001 Nov; 40(2):159-73. PubMed ID: 11682323
[TBL] [Abstract][Full Text] [Related]
8. Vinflunine, a novel microtubule inhibitor, suppresses calmodulin interaction with the microtubule-associated protein STOP.
Makarov AA; Tsvetkov PO; Villard C; Esquieu D; Pourroy B; Fahy J; Braguer D; Peyrot V; Lafitte D
Biochemistry; 2007 Dec; 46(51):14899-906. PubMed ID: 18052208
[TBL] [Abstract][Full Text] [Related]
9. Vinflunine: a new vision that may translate into antiangiogenic and antimetastatic activity.
Aparicio LM; Pulido EG; Gallego GA
Anticancer Drugs; 2012 Jan; 23(1):1-11. PubMed ID: 22027536
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of vinflunine: effector pathways and potential for synergies.
Braguer D; Barret JM; McDaid H; Kruczynski A
Semin Oncol; 2008 Jun; 35(3 Suppl 3):S13-21. PubMed ID: 18538174
[TBL] [Abstract][Full Text] [Related]
11. Clinical activity of vinflunine in transitional cell carcinoma of the urothelium and other solid tumors.
Bellmunt J; Delgado FM; George C
Semin Oncol; 2008 Jun; 35(3 Suppl 3):S34-43. PubMed ID: 18538178
[TBL] [Abstract][Full Text] [Related]
12. Microtubules: a dynamic target in cancer therapy.
Pasquier E; Kavallaris M
IUBMB Life; 2008 Mar; 60(3):165-70. PubMed ID: 18380008
[TBL] [Abstract][Full Text] [Related]
13. New insights into Vinca alkaloids resistance mechanism and circumvention in lung cancer.
Zhang Y; Yang SH; Guo XL
Biomed Pharmacother; 2017 Dec; 96():659-666. PubMed ID: 29035832
[TBL] [Abstract][Full Text] [Related]
14. Anticancer therapy with novel tubulin-interacting drugs.
Kavallaris M; Verrills NM; Hill BT
Drug Resist Updat; 2001 Dec; 4(6):392-401. PubMed ID: 12030786
[TBL] [Abstract][Full Text] [Related]
15. Microtubule alterations and resistance to tubulin-binding agents (review).
Drukman S; Kavallaris M
Int J Oncol; 2002 Sep; 21(3):621-8. PubMed ID: 12168109
[TBL] [Abstract][Full Text] [Related]
16. Microtubule active agents: beyond the taxane frontier.
Morris PG; Fornier MN
Clin Cancer Res; 2008 Nov; 14(22):7167-72. PubMed ID: 19010832
[TBL] [Abstract][Full Text] [Related]
17. Tubulin and microtubules as targets for anticancer drugs.
Hadfield JA; Ducki S; Hirst N; McGown AT
Prog Cell Cycle Res; 2003; 5():309-25. PubMed ID: 14593726
[TBL] [Abstract][Full Text] [Related]
18. Indibulin, a novel microtubule inhibitor, discriminates between mature neuronal and nonneuronal tubulin.
Wienecke A; Bacher G
Cancer Res; 2009 Jan; 69(1):171-7. PubMed ID: 19118000
[TBL] [Abstract][Full Text] [Related]
19. Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance.
Perez EA
Mol Cancer Ther; 2009 Aug; 8(8):2086-95. PubMed ID: 19671735
[TBL] [Abstract][Full Text] [Related]
20. Can mutations in gamma-actin modulate the toxicity of microtubule targeting agents?
Fojo T
J Natl Cancer Inst; 2006 Oct; 98(19):1345-7. PubMed ID: 17018774
[No Abstract] [Full Text] [Related]
[Next] [New Search]
